NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Eleven Biotherapeutics shares moved higher on Friday as investors continued to cheer the company's update last week in its earnings call about its Vicinium candidate to treat high-grade non-muscle invasive bladder cancer. Shares of CytRx also moved higher after announcing that it has regained compliance with the minimum bid price requirement with the NASDAQ.

RDI Initiates Coverage on:

Eleven Biotherapeutics, Inc.
http://www.rdinvesting.com/report/?ticker=EBIO

CytRx Corporation
http://www.rdinvesting.com/report/?ticker=CYTR

Eleven Biotherapeutics, Inc. shares closed up nearly 11% this past Friday with a little over 6 million shares traded. The stock was one of the most active biotech stocks in the market. It was the second day of gains for the stock after the company released its earnings report early last week. In the earnings call, management said it's on track to "complete recruitment in the Q1 2018 and report top line 3-month data in mid-2018" on a phase III trial of Vicinium. In the Phase II study, Vicinium had showed safety and efficacy in 46 patients, who were refractory or intolerant to BCG. Vicinium is a recombinant fusion protein in clinical development for the treatment of high-grade non-muscle invasive bladder cancer. The company said, "We expect our study will achieve results that are similar or better than the results from our Phase II study, which we believe will support Vicinium's potential as a therapeutic alternative to these patients. We look forward to finalizing trial and approaching the FDA regarding potential approval for Vicinium."

Access RDI's Eleven Biotherapeutics, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=EBIO

CytRx Corporation shares closed up 7.98% on nearly 900,000 shares on Friday. It was an exciting day for the biotech company that specializes in oncology as it announced it had received written notification last Thursday from the NASDAQ Listing Qualifications Department. The Department has notified CytRx that it has regained compliance with the minimum bid price requirement set forth in NASDAQ Listing Rule Section 5550(a)(2) for continued listing of its common stock on The NASDAQ Capital Market. The company also announced that it is engaging the services of a third-party firm to investigate and determine the extent of short selling in its common stock. The investigators already possess detailed records of shareholders. CytRx has a pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR? (Linker Activated Drug Release) technology platform.

Access RDI's CytRx Corporation Research Report at:
http://www.rdinvesting.com/report/?ticker=CYTR

Our Actionable Research on Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and CytRx Corporation (NASDAQ: CYTR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com